Trial Profile

Phase II randomized, double Blind, placebo-Controlled trial evaluating the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Nov 2021 Status changed from recruiting to discontinued, according to a Can-Fite BioPharma media release.
26 Nov 2021 According to a Can-Fite Biopharma media release, with the anticipated launch of Pfizer's oral COVID-19 antiviral drug candidate, he company has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials.
22 Apr 2021 According to a Can-Fite Biopharma media release, the trial has been expanded to two European countries, Romania and Bulgaria. Data are expected in Q4 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com